TY - JOUR T1 - The effect of intimate partner violence on women’s risk of HIV acquisition and engagement in the HIV treatment and care cascade: an individual-participant data meta-analysis of nationally representative surveys in sub-Saharan Africa JF - medRxiv DO - 10.1101/2022.08.04.22278331 SP - 2022.08.04.22278331 AU - S Kuchukhidze AU - D Panagiotoglou AU - MC Boily AU - S Diabaté AU - JW Eaton AU - F Mbofana AU - L Sardinha AU - L Schrubbe AU - H Stöckl AU - RK Wanyenze AU - M Maheu-Giroux Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/04/2022.08.04.22278331.abstract N2 - Background Achieving the 95-95-95 targets for HIV diagnosis, treatment, and viral load suppression (VLS) to end the HIV/AIDS epidemic hinges on eliminating structural inequalities, including intimate partner violence (IPV). Sub-Saharan Africa (SSA) has among the world’s highest prevalence of IPV and HIV. We aim to examine the impact of IPV on recent HIV infection and women’s engagement in the HIV care cascade.Methods We pooled individual-level data from nationally representative surveys with information on physical and/or sexual IPV and HIV in SSA (2000-2020). We used Poisson regressions with robust standard errors to estimate adjusted prevalence ratios (aPR) of past year experience of IPV on recent HIV infection (measured using recency assays), past-year HIV testing, antiretroviral therapy (ART) uptake, and VLS among ever-partnered (currently/formerly married or cohabitating) women. Models were adjusted for women’s age, age at sexual debut, residence type, marital status, education, and the survey’s identifier (proxy of country and year).Findings Fifty-seven surveys were available from thirty countries, encompassing 280,259 (Ni) individuals. One-fifth of women reported physical and/or sexual IPV in the past year. Six surveys had information on recent HIV infection and seven had data on ART uptake and VLS. Women experiencing past year IPV were 3·22 times (95%CI: 1·51-6·85, Ni=19,179) more likely to have a recent HIV infection, adjusting for potential confounders. Past year IPV was not associated with HIV testing (aPR=0·99, 95%CI: 0·98-1·01, Ni=274,506) or ART uptake (aPR=0·96, 95%CI:0·90-1·03, Ni=5,629). Women living with HIV (WLHIV) experiencing IPV in the past year were 9% less likely to achieve VLS (aPR=0·91, 95%CI: 0·85-0·98, Ni=5,627).Interpretation Past year IPV was associated with recent HIV acquisition and lower VLS among WLHIV. Preventing IPV is inherently imperative but eliminating IPV could also be crucial to ending HIV/AIDS.Funding Canadian Institutes of Health Research, Canada Research Chair, and Max E. Binz FellowshipResearch in ContextEvidence before this studyEvidence before this study Our study builds on more than two decades of research devoted to IPV and HIV.1-4 We summarized this scholarship by searching PubMed for empirical studies (April 8, 2022), without language restrictions using the terms: HIV AND women AND (violence OR intimate partner OR domestic violence OR GBV OR IPV) AND (Africa* OR sub-Sahara*).Several systematic and scoping reviews have been conducted on the links between IPV and HIV with mixed results.5-7 Most studies used HIV seropositivity as the outcome. In sub-Saharan Africa, a multi-country study found no association between IPV and HIV; however it has been subsequently suggested that women experiencing IPV have an increased risk of HIV seropositivity depending on the chosen referent group.8 Longitudinal studies in Uganda and South Africa suggest that women experiencing IPV are more likely to acquire HIV compared to those who are not.9,10 However, two other cohort studies among youth11 and serodiscordant couples12 did not find significant associations.Impacts of IPV on the HIV prevention and treatment cascade have also been studied. A 2015 meta-analysis of 13 cross-sectional studies, mostly from the United States, found that IPV is associated with lower ART use, adherence and VLS.13 For the first step in the cascade – HIV diagnosis– most included studies in a 2019 scoping review by Leddy14 did not find an association between IPV and HIV testing15-19; though two reported a reduction in testing associated with IPV among pregnant and postpartum women.20,21Evidence supports a negative relationship between IPV and ART adherence, though most studies focused on populations such as sex workers17, youth22, or pregnant/postpartum women.18,23-25 Quantitative evidence are sparse on ART uptake, but among five studies from high income settings, none showed an association between IPV and current ART use.13 Studies from Zambia and South Africa point to an association between IPV and unsuppressed viral loads among adolescents/youth26 and postpartum women.27Overall, comparison of estimates and outcomes is difficult due to a lack of standardization in survey instruments, recall period for IPV, considered IPV types, outcome measurement, and populations considered (e.g., pregnant and/or young women, sex workers).Added value of this studyAdded value of this study Using microdata from population-based surveys in the region with the highest HIV burden, we conducted the largest and most comprehensive study to date on the impacts of IPV on HIV: from HIV acquisition to the three most important steps of the treatment and care cascade. Our results generally corroborate previous findings, but we considerably expanded the scope of previous studies using recent experiences of IPV, consideration of partner characteristics, and estimating their impact on biomarker-based measures of HIV acquisition, ART coverage, and VLS.The implications of all the available evidenceThe implications of all the available evidence The 2021 Political Declaration on AIDS commits to eliminating sexual and gender-based violence, including IPV as key to combatting the AIDS epidemic. IPV is an urgent public health concern, and a barrier to the elimination of AIDS. Our results highlight the need for HIV programs to consider IPV along the full continuum of HIV prevention to treatment and care. Both IPV and HIV are preventable. Governments, societies, and communities need to explicitly recognize the IPV-HIV syndemic, and implement multisectoral response with social and economic components to eliminate gender-based violence and end AIDS.Competing Interest StatementMM-G reports an investigator-sponsored research grant from Gilead Sciences Inc., and contractual arrangements from the Institut national de santé publique du Québec (INSPQ), the Institut d'excellence en santé et services sociaux (INESSS), the World Health Organization, and the Joint United Nations Programme on HIV/AIDS (UNAIDS), all outside of the submitted work.Funding StatementThis study is funded by the Canadian Institutes of Health Research. MMG's research program is funded by a Canada Research Chair (Tier 2) in Population Health Modeling. SK received a Max E. Binz Fellowship from McGill University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All analyses were performed using secondary, de-identified data. DHS/AIS survey protocols are approved by the Internal Review Board of ICF International in Calverton (USA) and by the relevant country authorities for other surveys. Approval for data analyses was obtained from McGill University's Faculty of Medicine and Health Sciences Institutional Review Board (A12-B95-21B).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -